Related Experiment Video

Updated: Mar 28, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

8.1K

MALT1 Inhibition of Oral Carcinoma Cell Invasion and ERK/MAPK Activation

T Chiba1, Y Soeno2, Y Shirako2

  • 1Department of Biochemistry, School of Life Dentistry at Tokyo, The Nippon Dental University, Tokyo, Japan.

Journal of Dental Research
|December 25, 2015
PubMed

Insights

Mucosa-associated lymphoid tissue 1 (MALT1) suppresses oral carcinoma invasion by inhibiting cell proliferation, migration, and matrix degradation. MALT1 targets the ERK/MAPK pathway, acting as a suppressor of oral cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Mucosa-associated lymphoid tissue 1 (MALT1) is crucial for NF-κB activation in lymphocytes.
  • MALT1 expression is reduced in oral carcinoma at the invasive front, correlating with poor prognosis.
  • The precise mechanism by which MALT1 influences oral cancer progression remains unclear.

Purpose of the Study:

  • To investigate the role of MALT1 in oral carcinoma invasion and progression.
  • To elucidate the molecular pathways targeted by MALT1 in oral cancer cells.

Main Methods:

  • Stable expression of wild-type (wtMALT1) and dominant-negative (∆MALT1) MALT1 in HSC2 oral carcinoma cells.
  • Invasion assays using basement membrane matrices and collagen gels.
  • Short interfering RNA (siRNA) transfections to confirm gene downregulation.
  • Reporter assays and immunoblot analysis to assess pathway activation.
  • Orthotopic implantation of modified cells in mouse models.

Main Results:

  • wtMALT1 expression reduced cell invasion, proliferation, and migration.
  • ∆MALT1 expression led to aggressive invasion into collagen gels.
  • MALT1 downregulated matrix metalloproteinase 2 and 9 (MMP2/9) expression.
  • MALT1 inhibited ERK/MAPK activation, independent of the NF-κB pathway.
  • In vivo studies showed wtMALT1 suppressed tumor formation, while ∆MALT1 promoted rapid, invasive tumor growth.

Conclusions:

  • MALT1 acts as a suppressor of oral carcinoma invasion and progression.
  • MALT1 inhibits proliferation, migration, and extracellular matrix degradation.
  • The ERK/MAPK pathway is a key target inhibited by MALT1 in oral cancer.
Keywords:
human MALT1 proteinmatrix metalloproteinasesmitogen-activated protein kinasesmouth neoplasmneoplasm invasivenesssquamous cell carcinoma

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K
Induction and Analysis of Epithelial to Mesenchymal Transition10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.7K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K